Gujarat Themis Biosyn LimitedUnclassifiedGUJTHEM
Q1 FY27 earnings callGujarat Themis Biosyn Limited
The company is in a transformational phase, focusing on becoming a fermentation-based CDMO through major acquisitions and capacity expansion, while posting strong quarterly growth.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue from Operations | INR 43.8 crores | 22.1% | |
| EBITDA | INR 20.8 crores | 49.4% | |
| EBITDA Margin | 47.5% | 867 basis points | |
| Profit After Tax | INR 11.1 crores | 22.1% |
TL;DR
- Revenue grew 22.1% YoY to INR 43.8 crores, with EBITDA up 49.4% and margin expanding 867 basis points.
- Management highlighted two major acquisitions: MicroBiopharm Japan for technology and Sanofi's portfolio for global commercial reach.
- New fermentation and API capacities are becoming operational, aiming to move downstream and diversify the product portfolio.
- The company aims to transform into an integrated, fermentation-led pharmaceutical platform and CDMO.
- Balance sheet is described as healthy, providing flexibility for growth investments.
Said on the call
“Our strategic initiatives undertaken over the last 18 to 24 months are all connected by one common objective, transforming GTBL into an integrated fermentation-led pharmaceutical platform.”
From the Q&A
| Topic | What management said |
|---|---|
| Acquisition Financing and Sense | An analyst questioned the financial sense of the ~INR 3000 crore acquisitions given potential interest burden; management clarified interest costs in target geographies are lower than the assumed 10%, the business is cash flow positive, and the Sanofi deal closure is 6-9 months away due to regulatory approvals. |
| API Block Delays | Asked about the 2-year delay in API revenues, management stated the delay was due to lack of fermentation capacity; new capacity is now ready, and output should start this quarter. |
| Merger with Themis Medicare | Management explained the planned merger was called off to avoid diluting GTBL's focus on becoming a fermentation-based CDMO, rather than pursuing domestic brand businesses. |
| MicroBiopharm Japan (MBJ) Commercialization | Analysts asked which MBJ platforms are commercialized; management stated all except ADCs are commercialized with at least one product, but declined to give revenue splits by vertical. |
| New Capacity Utilization | On the doubled fermentation capacity, management said it will be fully operational by month-end, running at full scale (0 or 100 utilization), targeting all intermediate users. |
| Sanofi Portfolio Manufacturing | Clarified that post-acquisition, manufacturing will transition via CMOs over up to 3 years, with plans to integrate GTBL's own APIs into the supply chain for margin improvement. |
| Future Growth and Capex | Management stated most capex is done (~INR 10-15 crores left), aiming for high-teen growth on a base case, with asset turns of 1.4x-1.5x on the new ~INR 200 crores of productive assets. |
| Risk and Integration of Acquisitions | In response to concerns about digesting large overseas acquisitions, management emphasized both target businesses are historically steady, they are not taking on turnaround risk, and expect synergy projects to start within the first year. |
Guidance
- Output from expanded fermentation and API capacity should start to be seen from this quarter (Q2 FY27) and fully in the second half of the year.
- Targeting high-teen growth on a base case basis over the next 3-5 years.
- Expect some synergy projects with MicroBiopharm Japan to start within the first year of acquisition.
- The Sanofi portfolio acquisition is expected to close in about 6 to 9 months, with a long-stop date of June next year.
- Phase 1 of the hybrid power plant is expected to go live in September, improving EBITDA margins.
- Promoter pledge is expected to reduce significantly within a year to 15 months.
- Remaining capex for the base business is minimal, around INR 10-15 crores, with total FY27 capex including maintenance around INR 20 crores.
Source
Summary written from the transcript filed by Gujarat Themis Biosyn Limited for the call held on 10 Aug 2026; published 18 Aug 2026, 20:07 IST.